Servier and LabCentral announced that the Servier Spark Award* 2021 goes to New Equilibrium Biosciences, a biotech that develops small molecules targeting intrinsically disordered proteins. This award will allow New Equilibrium Biosciences to continue developing its preclinical programs in Oncology and potentially in other therapeutic areas.
New Equilibrium Biosciences develops small molecules from original structural studies of intrinsically disordered proteins, proteins involved in different pathologies, in Oncology or in Neurology. Due to the dynamism of their structures, these proteins are generally difficult to target and to inhibit. The original approach of New Equilibrium Biosciences could allow breakthroughs in the field. The first indications on which New Equilibium Biosciences are focusing are breast cancer or rare cancers.
“Intrinsically disordered proteins represent an attractive class of potential drug targets across a variety of disease indications and states. New Equilibrium Bio’s synergistic data- and wet-lab driven approach, backed by a strong team of scientific entrepreneurs, is well suited to tackle this challenge in two of Servier’s therapeutic areas of interest. We are proud to support their efforts at this early stage.”
*The Spark Award (also known as Golden Ticket) is part of Servier’s sponsorship with LabCentral. This award allows the winning start-up to have access to LabCentral’s facilities, by covering the operating costs of a researcher for one year, thus giving the wining biotech the means to focus all its efforts on their scientific development. This prize is also intended to forge links between the winning biotech and Servier’s research teams, by opening a scientific dialogue.